PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
13.79%
Growth of 13.79% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
365.67%
Cost growth of 365.67% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
-55.89%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
82.86%
Margin change of 82.86% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
86.76%
R&D change of 86.76% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
63.48%
G&A change of 63.48% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
33.89%
Marketing expense change of 33.89% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
761.64%
Other expenses change of 761.64% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
68.11%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.30%. Jim Chanos would check for waste.
5.19%
Total costs growth near Drug Manufacturers - Specialty & Generic median of 5.19%. Charlie Munger would verify industry norms.
-7.90%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
153.97%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.05%. Jim Chanos would check for overinvestment.
-115.86%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -4.14%. Seth Klarman would investigate causes.
1033.24%
Margin change of 1033.24% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-110.68%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -13.18%. Seth Klarman would investigate causes.
-85.15%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is -0.00%. Seth Klarman would investigate causes.
-114.26%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-141.47%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is -7.39%. Seth Klarman would investigate causes.
-136.45%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-143.97%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is -0.43%. Seth Klarman would investigate advantages.
-140.68%
Net income decline while Drug Manufacturers - Specialty & Generic median is -7.92%. Seth Klarman would investigate causes.
-135.75%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-129.18%
EPS decline while Drug Manufacturers - Specialty & Generic median is -4.77%. Seth Klarman would investigate causes.
-128.65%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -4.06%. Seth Klarman would investigate causes.
40.06%
Share count change of 40.06% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
37.54%
Diluted share change of 37.54% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.